Crizotinib nearly doubles progression-free survival in patients with ALK-positive lung cancer

被引：0
|
作者：
Mayor, Susan
机构：
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2012年 / 73卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：610 / 610
页数：1
相关论文
共 50 条
  • [41] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2027 - 2039
  • [42] Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls
    Shaw, A. T.
    Yeap, B. Y.
    Solomon, B. J.
    Riely, G. J.
    Iafrate, A. J.
    Shapiro, G.
    Costa, D. B.
    Butaney, M.
    Ou, S. I.
    Maki, R. G.
    Bang, Y.
    Varella-Garcia, M.
    Salgia, R.
    Wilner, K. D.
    Kulig, K.
    Selaru, P.
    Tang, Y.
    Kwak, E. L.
    Clark, J. W.
    Camidge, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] The efficacy of dose reduced crizotinib for advanced ALK-positive nonsmall cell lung cancer
    Naito, M.
    Naoki, Y.
    Takata, S.
    Ishii, S.
    Taniguchi, Y.
    Saijo, N.
    Tamiya, A.
    Omachi, N.
    Okishio, K.
    Morita, S.
    Tanaka, A.
    Shiroyama, T.
    Morishita, N.
    Suzuki, H.
    Okamoto, N.
    Hirashima, T.
    Atagi, S.
    ANNALS OF ONCOLOGY, 2017, 28 : 133 - 133
  • [44] Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib
    Pailler, Emma
    Oulhen, Marianne
    Ross, Kirsty
    Billiot, Fanny
    Auger, Nathalie
    Borger, Isabelle
    NgoCamus, Maud
    Remon-Masip, Jordi
    Planchard, David
    Soria, Jean-Charles
    Besse, Benjamin
    Farace, Francoise
    CANCER RESEARCH, 2016, 76
  • [45] EFFICACY AND TOXICITY OF CRIZOTINIB FOR PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC
    Asao, T.
    Honma, Y.
    Suina, K.
    Muraki, K.
    Shukuya, T.
    Ohashi, R.
    Koyama, R.
    Shimada, N.
    Sakuraba, S.
    Takahashi, K.
    ANNALS OF ONCOLOGY, 2013, 24
  • [46] A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
    Dikopf, Alana
    Wood, Kevin
    Salgia, Ravi
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 485 - 493
  • [47] Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
    Cui, Shaohua
    Zhao, Yizhuo
    Gu, Aiqin
    Ge, Xiaoxiao
    Song, Yanyan
    Zhang, Wei
    Lou, Yuqing
    Dong, Lili
    Han, Baohui
    Jiang, Liyan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [48] Regarding the prognostic factors in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Hu, Limei
    Xie, Youjun
    Zhao, Hongying
    PULMONOLOGY, 2024, 30 (04): : 406 - 407
  • [49] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Nishio, Makoto
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Solomon, Benjamin J.
    Shaw, Alice T.
    Hashigaki, Satoshi
    Ohki, Emiko
    Usari, Tiziana
    Paolini, Jolanda
    Polli, Anna
    Wilner, Keith D.
    Mok, Tony
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
  • [50] CLINICAL BENEFIT OF CONTINUING CRIZOTINIB BEYOND INITIAL DISEASE PROGRESSION IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
    Ou, Sai-Hong I.
    Riely, Gregory J.
    Tang, Yiyun
    Kim, Dong-Wan
    Otterson, Gregory A.
    Crino, Lucio
    Bartlett, Cynthia H.
    Cohen, Darrel P.
    Clark, Jeffrey W.
    Jaenne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S294 - S294
12345